Advanced searches left 3/3

Esophageal Cancer - Crossref

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

A Key Role for Early Growth Response-1 and Nuclear Factor-κB in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer

In 80% of esophageal tumor tissues examined, immunohistochemistry revealed that EGR-1 is overexpressed. In addition, EGR-1 is present in all esophageal cancer cell lines that were tested. A 55% decrease in EGR-1 protein levels, a 50% decrease in cell proliferation, a 50% decrease in cyclin-dependent kinase 4 levels, and a twofold increase in p27Kip1 cells associated with a G2-M cell cycle arrest were all observed in stably transfected with EGR-1 short hairpin RNA. Since EGR-1 knockdown is downstream of GRO/CXCR2 signaling, a marked increase in IB expression was also observed in GRO-RNA interference-expressing WHCO1 cells. In addition, p65 mRNA levels in cells treated with either short hairpin RNA EGR-1 or small interfering RNA EGR-1 were also reduced in cells treated with either short hairpin RNA EGR-1 or small interfering RNA EGR-1. These results show that EGR-1 and nuclear factor-B mediate GRO/CXCR2 expression in esophageal cancer and may be target molecules for therapeutic intervention.

Source link: https://doi.org/10.1158/1541-7786.mcr-08-0472


Difference between “Lung Age” and Real Age as a Novel Predictor of Postoperative Complications, Long-Term Survival for Patients with Esophageal Cancer after Minimally Invasive Esophagectomy

Background This research was designed to see if the difference between "lung age" and actual age could be helpful in predicting postoperative complications and long-term survival in patients with esophageal cancer patients with minimally invasive esophagectomy. Methods This retrospective cohort analysis included 625 consecutive patients who had undergone MIE. Patients were divided into three groups: group A: L–R 0; group B: L–R 0; Group B: L–R 0; group C: L–R 15. Concerning overall survival, there was a major difference between group A and group B+ C. Conclusions Esophageal cancer patients with impaired respiratory health and poorer prognosis were at a greater risk of severe postoperative complications and poorer prognosis than those with normal pulmonary function. The difference between "lung age" and "real age" seems to be a novel and potential predictor of severe postoperative complications and long-term survival.

Source link: https://doi.org/10.3389/fsurg.2022.794553


S100A14: Novel Modulator of Terminal Differentiation in Esophageal Cancer

To better understand esophageal carcinogenesis, it is important to identify which genes that regulate differentiation show altered or decreased capacity in esophageal cancer cells. The present study used immunohistochemistry analysis of S100A14 in clinical samples of esophageal squamous cell carcinoma to show that decreased S100A14 is strongly associated with poor differentiation. Both mRNA and protein expression of S100A14 were also enhanced on 12-O-tetra-decanoylphorbol-13-acetate and calcium-induced esophageal cancer cell differentiation, respectively. Overexpression of S100A14 resulted in a G1-phase cell cycle arrest and stimulated calcium-inhibited cell growth, resulting in a G1-phase cell cycle arrest and promoted calcium-inhibited cell proliferation. S100A14 is transcriptionally controlled by JunB, according to SCC results, and S100A14 and JunB status were significantly associated with ESCC tissue. In summary, these results reveal that S100A14 is transcriptionally controlled by JunB and instrumental in cell differentiation.

Source link: https://doi.org/10.1158/1541-7786.mcr-13-0317


Migfilin Regulates Esophageal Cancer Cell Motility through Promoting GSK-3β–Mediated Degradation of β-Catenin

We have established the roles of migfilin in esophageal cancer cells as well as the mechanisms involved. We show that the expression of migfilin is positively associated with clinical metastasis, and that the enforceable expression of migfilin impair cell motility by lowered free -catenin levels are negatively linked to cell motility. Moreover, migfilin promoted -catenin degradation by reinforcing the link between -catenin and GSK-3. These results suggest that the expression level of migfilin in ESCCs is inversely linked to clinical metastasis status, and that migfilin inhibits ESCC cell migration at least in part by encouraging chemophytin degradation.

Source link: https://doi.org/10.1158/1541-7786.mcr-11-0419


Artesunate Inhibits the Development of Esophageal Cancer by Targeting HK1 to Reduce Glycolysis Levels in Areas With Zinc Deficiency

Zin deficiency promotes the cell cycle, thus increasing the risk of EC in areas with a high incidence of EC. In this research, we first established how artesunate inhibits EC in vitro, then demonstrated that artesunate could reverse ZD-promoted EC progression before EC occured in vivo. Artesunate has an anti-EC role by inhibiting aerobic glycolysis, and it could be a drug that prevents EC in areas at a high risk of EC.

Source link: https://doi.org/10.3389/fonc.2022.871483


Long noncoding RNA SNHG16 facilitates esophageal cancer cell proliferation and self-renewal through the microRNA-802/PTCH1 axis

This study was conducted to determine the effect and mechanism of long-coding RNA SNHG16 on esophageal cancer cell proliferation and self-renewal. In EC9706 and KYSE150 cells, flow cytometry was used to separate cancer stem cells. In comparison to colony and tumorsphere numbers, cell proliferation in EC cells was measured. The gene expression in the Hedgehog pathway was determined. Nude mice were injected with SNHG16-silenced EC9706 cells to determine the tumorigenicity of EC9706 cells. Upregulated SNHG16 expression was discovered in CSCs, although the expression of CSCs was reduced during CSC differentiation. In addition, SNHG16 and PTCH1 remained closely bound to miR-802, while SNHG16 and PTCH1 orchestrated the miR-802/PTCH1 axis to launch the Hedgehog route. Conclusion: SNHG16 acts as a sponge of miR-802 to upregulate PTCH1 and activate the Hedgehog pathway, thus encouraging EC cell proliferation and self-renewal in a sequential fashion.

Source link: https://doi.org/10.2174/0929867329666220510090418


Pembrolizumab for the treatment of advanced esophageal cancer

Pemous cell carcinoma patients with a total positive score of 10. Pembrolizumab plus doublet chemotherapy also has a significant survival advantage among patients with advanced EC as a first-line therapy compared to chemotherapy alone. Pembrolizumab plus chemotherapy should be the first-line therapy for patients with advanced EC, regardless of histology or combined positive score.

Source link: https://doi.org/10.2217/fon-2022-0108


The Epidemiological Trend of Esophageal Cancer in Mumbai, India, Over the Past Fifteen Years

Abstract Background: There has been a consistent shift in the histopathological spectrum of esophageal cancer towards adenocarcinoma seen in developed countries. Materials and Methods: We retrospectively evaluated patients with histologically confirmed esophageal cancer who were admitted to the Tata Memorial Hospital between 2003 and 2018. 592 patients with esophageal cancer died, with M:F of 2. 5:1. 57 years old; out of the 4912 patients in whom no history of tobacco or alcohol use had been elicited, 1360 patients denied substance abuse. In 6413 patients, Squamous cell carcinoma was the histological type of histological disease. Female sex and substance use were positively related to squamous cell carcinoma, according to a multivariate analysis, while comorbidities and the primary site in lower esophagus/GEJ were positively related to adenocarcinoma, and moderate obesity were positively correlated with adenocarcinoma. Squamous cell histology has been found in four out of five Indian patients with esophageal cancer.

Source link: https://doi.org/10.21203/rs.3.rs-1166218/v1


The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results

During their initial chemoradiotherapy therapy course, weight loss is a common occurrence in unresectable esophageal cancer patients. This review looked at the prognostic value of weight changes during dCRT in unresectable EC patients. Patients with weight loss between 4% and > 4% during dCRT were 59. 6 months and 9. 7 months, respectively. Our analysis revealed that weight loss of 4% during the dCRT course is a beneficial prognostic predictor for cT4b EC patients.

Source link: https://doi.org/10.3390/life12050706

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions